|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007137,
umls-concept:C0008838,
umls-concept:C0079460,
umls-concept:C0205195,
umls-concept:C0205390,
umls-concept:C0206558,
umls-concept:C0441771,
umls-concept:C0460004,
umls-concept:C0751177,
umls-concept:C0751688,
umls-concept:C1518581,
umls-concept:C1522449,
umls-concept:C2603343
|
|
pubmed:issue |
15
|
|
pubmed:dateCreated |
2010-7-30
|
|
pubmed:abstractText |
This study sought to define the recommended dose of JS1/34.5-/47-/GM-CSF, an oncolytic herpes simplex type-1 virus (HSV-1) encoding human granulocyte-macrophage colony-stimulating factor (GM-CSF), for future studies in combination with chemoradiotherapy in patients with squamous cell cancer of the head and neck (SCCHN).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:BhideShreerang ASA,
pubmed-author:ClarkePeter MPM,
pubmed-author:CoffinRobertR,
pubmed-author:GoldsweigHowardH,
pubmed-author:HarringtonKevin JKJ,
pubmed-author:HickeyJenniferJ,
pubmed-author:HingoraniMohanM,
pubmed-author:McNeishIain AIA,
pubmed-author:NewboldKate LKL,
pubmed-author:NuttingChristopher MCM,
pubmed-author:RenoufLouise CLC,
pubmed-author:SibtainAmenA,
pubmed-author:TanayMary AnneMA,
pubmed-author:ThwayKhinK
|
|
pubmed:copyrightInfo |
(c) 2010 AACR.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4005-15
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:20670951-Adult,
pubmed-meshheading:20670951-Aged,
pubmed-meshheading:20670951-Antibodies, Viral,
pubmed-meshheading:20670951-Antigens, Viral,
pubmed-meshheading:20670951-Antineoplastic Agents,
pubmed-meshheading:20670951-Carcinoma, Squamous Cell,
pubmed-meshheading:20670951-Cisplatin,
pubmed-meshheading:20670951-Combined Modality Therapy,
pubmed-meshheading:20670951-Female,
pubmed-meshheading:20670951-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:20670951-Head and Neck Neoplasms,
pubmed-meshheading:20670951-Humans,
pubmed-meshheading:20670951-Immunohistochemistry,
pubmed-meshheading:20670951-Kaplan-Meier Estimate,
pubmed-meshheading:20670951-Male,
pubmed-meshheading:20670951-Maximum Tolerated Dose,
pubmed-meshheading:20670951-Middle Aged,
pubmed-meshheading:20670951-Neoplasm Staging,
pubmed-meshheading:20670951-Oncolytic Virotherapy,
pubmed-meshheading:20670951-Radiotherapy,
pubmed-meshheading:20670951-Simplexvirus,
pubmed-meshheading:20670951-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck.
|
|
pubmed:affiliation |
Institute of Cancer Research, 237 Fulham Road, London, United Kingdom. Kevin.Harrington@icr.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
